Association of Faecal Calprotectin Level and Combined Endoscopic and Radiological Healing in Patients With Crohn’s Disease Receiving Anti-tumour Necrosis Factor Therapy

• Published in: Journal of Crohn's and colitis 2020-09, Vol.14 (9), p.1231-1240
• Main Authors: Noh, Soo Min, Oh, Eun Hye, Park, Seong Ho, Lee, Jung Bok, Kim, Jin Yong, Park, Jae Cheol, Kim, Jeongseok, Ham, Nam Seok, Hwang, Sung Wook, Park, Sang Hyoung, Yang, Dong-Hoon, Byeon, Jeong-Sik, Myung, Seung-Jae, Yang, Suk-Kyun, Ye, Beyong Duk
• Format: Article
• Language: English
• ISSN: 1873-9946; 1876-4479
• DOI: 10.1093/ecco-jcc/jjaa042

Abstract Background and Aims Combined endoscopic and radiological healing, or deep healing, is associated with favourable outcomes in patients with Crohn’s disease; thus, a non-invasive biomarker for predicting deep healing would be invaluable. We evaluated the usefulness of faecal calprotectin for predicting deep healing in patients with Crohn’s disease receiving anti-tumour necrosis factor [TNF] therapy. Methods We analysed the records of patients with Crohn’s disease who received anti-tumour necrosis factor therapy and underwent endoscopic evaluation, radiological evaluation, and faecal calprotectin measurement within a period of 3 months between August 2017 and November 2018. Results of endoscopic and radiological studies were independently reviewed by two gastrointestinal endoscopists and a gastrointestinal radiologist, respectively. Serum C-reactive protein and albumin were also measured. Results Out of 268 patients analysed, 77 [28.7%] had deep healing, 36 [13.4%] had endoscopic healing only, 36 [13.4%] had radiological healing only, and 119 [44.4%] had neither. The median duration of anti-TNF treatment was 40.0 months. The deep healing group had the lowest median faecal calprotectin level [56.5 mg/kg] among the four groups [p